How many 6-K filings has Redhill Biopharma Ltd. filed?

Redhill Biopharma Ltd. (RDHL) has 50 6-K (Foreign Current Report) filings on record, spanning Sep 2024 to Apr 2026.

What is a 6-K filing?

A 6-K is an SEC filing known as "Foreign Current Report." Current report filed by foreign private issuers for material events. Equivalent to the 8-K for domestic companies.

Where can I read Redhill Biopharma Ltd. 6-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Redhill Biopharma Ltd. 6-K filings, including risk assessment, sentiment analysis, and key financial figures.

Redhill Biopharma Ltd. (RDHL) — 6-K Filings

All 6-K filings from Redhill Biopharma Ltd.. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

RedHill Biopharma Files 6-K Report — Apr 30, 2026 Risk: low
RedHill Biopharma Ltd. filed a Form 6-K on April 30, 2026. This report is for a foreign issuer and provides information as of the period ending April 30, 2026.
6-K Filing — Apr 27, 2026
6-K Filing — Apr 22, 2026
6-K Filing — Apr 14, 2026
RedHill Biopharma Files 6-K with Pro Forma Financials — Dec 31, 2025 Risk: low
RedHill Biopharma Ltd. filed a 6-K report on December 31, 2025, incorporating unaudited pro forma condensed consolidated financial information. This information
RedHill Biopharma Secures $10M Equity Line — Dec 23, 2025 Risk: medium
On December 19, 2025, RedHill Biopharma Ltd. entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. This agreement allows RedHill Biopharma
6-K Filing — Dec 15, 2025
6-K Filing — Dec 1, 2025
6-K Filing — Nov 26, 2025
6-K Filing — Nov 4, 2025
RedHill Biopharma Faces Nasdaq Delisting Risk — Oct 22, 2025 Risk: medium
RedHill Biopharma Ltd. received a notification from the Nasdaq staff on October 22, 2025, indicating that the company is not in compliance with Nasdaq Listing R
RedHill Biopharma Amends Share Purchase Agreement — Oct 21, 2025 Risk: medium
RedHill Biopharma Ltd. announced an amendment to its Any Market Purchase Agreement with Alumni Capital LP, originally entered into on June 20, 2025. This amendm
RedHill Biopharma Files 6-K, Incorporates Prior Filings — Oct 20, 2025 Risk: low
RedHill Biopharma Ltd. filed a Form 6-K on October 20, 2025, to report its status as a foreign private issuer. This filing incorporates by reference previous re
RedHill Biopharma Secures $1.8M+ Middle East Deal for Talicia® — Oct 6, 2025 Risk: medium
RedHill Biopharma Ltd. announced on October 6, 2025, a new Middle East distribution deal for its drug Talicia®. The agreement is valued at over $1.8 million, pl
RedHill Biopharma Wins $10M Court Appeal Against Kukbo — Sep 29, 2025 Risk: medium
RedHill Biopharma Ltd. announced on September 29, 2025, that it won a New York Supreme Court appeal, upholding a $10 million summary judgment against Kukbo. Thi
RedHill Biopharma Files 6-K, Details Hyloris Deal & Warrants — Sep 5, 2025 Risk: medium
RedHill Biopharma Ltd. filed a 6-K report for the period ending June 30, 2025. The filing includes information related to their Movantik product and an exclusiv
RedHill Biopharma Wins $1.8M Legal Costs, Totaling $10.05M — Aug 20, 2025 Risk: medium
RedHill Biopharma Ltd. announced on August 20, 2025, that the New York Supreme Court awarded them $1.8 million in legal costs and expenses. This award is in add
RedHill Biopharma Receives $1.1M in Talicia Licensing Payments — Aug 18, 2025 Risk: low
RedHill Biopharma Ltd. announced on August 18, 2025, that it received licensing payments totaling $1.1 million for its Talicia® drug. This filing incorporates b
RedHill Biopharma Files 6-K, Incorporates by Reference — Aug 14, 2025 Risk: low
RedHill Biopharma Ltd. filed a Form 6-K on August 14, 2025, to report its status as a foreign private issuer. This filing is incorporated by reference into seve
RedHill Biopharma Gets FDA Nod for Crohn's Drug — Jul 21, 2025 Risk: medium
RedHill Biopharma Ltd. announced on July 21, 2025, that it received positive feedback from the FDA regarding the pathway to approval for its drug RHB-204, inten
RedHill Biopharma Starts Expanded Phase 2 Prostate Cancer Study — Jul 1, 2025 Risk: medium
RedHill Biopharma Ltd. announced on July 1, 2025, that it has initiated patient recruitment for an expanded Phase 2 study of opaganib in combination with darolu
RedHill Biopharma Secures Up To $10M Equity Line — Jun 25, 2025 Risk: medium
On June 20, 2025, RedHill Biopharma Ltd. entered into an Any Market Purchase Agreement with Alumni Capital LP. This agreement allows RedHill Biopharma to sell u
RedHill Biopharma Shareholders Approve All Resolutions — May 27, 2025 Risk: low
RedHill Biopharma Ltd. announced that at its adjourned Annual General Meeting of Shareholders on May 26, 2025, all proposed resolutions were approved. Key among
RedHill Biopharma Updates on Share Purchase Warrants — May 19, 2025 Risk: medium
RedHill Biopharma Ltd. is providing an update on its ordinary share purchase warrants, originally issued on March 29, 2024, to certain investors. These warrants
RedHill Biopharma Wins $8.25M Judgment, Freezes Kukbo Assets — May 13, 2025 Risk: medium
RedHill Biopharma Ltd. announced on May 13, 2025, that it secured an asset freeze against Kukbo following a New York Supreme Court summary judgment win. This ju
RedHill Biopharma Adjourns Shareholder Meeting Due to Lack of Quorum — May 5, 2025 Risk: low
RedHill Biopharma Ltd. announced the adjournment of its Annual General Meeting of Shareholders, originally scheduled for May 5, 2025, due to a lack of legal quo
RedHill Biopharma Supports H. Pylori Education Launch — May 2, 2025 Risk: low
RedHill Biopharma Ltd. announced on May 2, 2025, that a Medscape educational program on H. pylori, supported by the company, will launch at a major gastroentero
RedHill Biopharma's COVID-19 Drug RHB-107 Gets Key China Patent Allowance — Apr 28, 2025 Risk: medium
RedHill Biopharma Ltd. announced on April 28, 2025, that it has secured the allowance of a key Chinese patent application for its proprietary COVID-19 treatment
RedHill Biopharma Faces Nasdaq Delisting Risk — Apr 17, 2025 Risk: medium
RedHill Biopharma Ltd. received a notification from Nasdaq on April 17, 2025, indicating a deficiency in its minimum stockholders' equity. The company is requir
RedHill Biopharma Opaganib Data Published — Apr 16, 2025 Risk: medium
RedHill Biopharma Ltd. announced on April 16, 2025, that positive data for its drug opaganib regarding weight loss and diabetes was published. The company sugge
RedHill Biopharma Reports 2024 Financials & Highlights — Apr 10, 2025 Risk: medium
RedHill Biopharma Ltd. announced its full-year 2024 financial results and operational highlights via a press release filed on April 10, 2025. The company is a f
RedHill Biopharma Files 6-K Report — Apr 8, 2025 Risk: low
RedHill Biopharma Ltd. filed a Form 6-K on April 8, 2025, to report its status as a foreign private issuer. This filing is incorporated by reference into severa
RedHill Biopharma Schedules May 5th Shareholder Meeting — Apr 1, 2025 Risk: low
RedHill Biopharma Ltd. filed a Form 6-K on April 1, 2025, to report its notice and proxy statement for the annual general meeting of shareholders scheduled for
RedHill Biopharma Schedules Annual General Meeting for May 5 — Mar 26, 2025 Risk: low
RedHill Biopharma Ltd. has filed a Form 6-K on March 26, 2025, to report the notice of its annual general meeting of shareholders. The meeting is scheduled to t
RedHill Biopharma Seeks UK Approval for Talicia® — Mar 18, 2025 Risk: medium
RedHill Biopharma Ltd. announced on March 18, 2025, that it will submit its FDA-approved Talicia® for UK marketing authorization. This submission aims to expand
RedHill Biopharma Advances Crohn's Disease Program on Positive Phase 3 Data — Mar 12, 2025 Risk: medium
RedHill Biopharma Ltd. announced on March 12, 2025, that it is advancing its late-stage Crohn's disease program based on statistically significant positive Phas
RedHill Biopharma Presents Business Update at Sachs Forum — Feb 27, 2025 Risk: low
RedHill Biopharma Ltd. filed a Form 6-K on February 27, 2025, to report a business update presented at the Sachs European Life Sciences CEO Forum. The filing in
RedHill Biopharma Licenses RHB-102 to Hyloris for up to $60M — Feb 25, 2025 Risk: medium
RedHill Biopharma Ltd. announced on February 25, 2025, that it has licensed its drug candidate RHB-102 for worldwide commercialization, excluding North America,
RedHill Biopharma Starts Phase 2 Prostate Cancer Study — Feb 4, 2025 Risk: medium
RedHill Biopharma Ltd. announced on February 4, 2025, the initiation of a Phase 2 study for its drug candidate, opaganib, in combination with darolutamide, for
RedHill Biopharma Enters At-the-Market Offering Agreement — Feb 3, 2025 Risk: medium
On February 3, 2025, RedHill Biopharma Ltd. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC. This agreement allows the company
RedHill's Talicia Gains Humana Coverage, Expands Reach — Jan 21, 2025 Risk: medium
RedHill Biopharma Ltd. announced on January 21, 2025, that its drug Talicia® now has coverage for 8 million lives through Humana®'s Part D plan. Additionally, n
RedHill's Opaganib Shows Radioprotective Activity in New Study — Dec 10, 2024 Risk: medium
RedHill Biopharma Ltd. announced on December 10, 2024, that a new study by the RNCP/NIAID confirmed the radioprotective activity of its drug, opaganib, for gast
RedHill Biopharma Wins $8M Court Judgment — Dec 2, 2024 Risk: medium
RedHill Biopharma Ltd. announced on December 2, 2024, that it was awarded a judgment of approximately $8 million plus costs by the New York Supreme Court. This
RedHill Biopharma to Present at World Congress of Gastroenterology — Oct 28, 2024 Risk: low
RedHill Biopharma Ltd. announced on October 28, 2024, that it has been selected to present at the 2024 World Congress of Gastroenterology at ACG 2024. The prese
RedHill Biopharma Announces New Collaboration — Oct 22, 2024 Risk: medium
RedHill Biopharma Ltd. filed a Form 6-K on October 22, 2024, to report information as a foreign private issuer. The filing includes a press release titled "RedH
RedHill Biopharma Files 6-K, Hints at U.S. Development — Oct 15, 2024 Risk: medium
RedHill Biopharma Ltd. filed a Form 6-K on October 15, 2024, to report a press release titled "RedHill Biopharma Secures U.S.". The filing indicates the company
RedHill Biopharma Files 6-K, Announces Medi-Cal Deal — Oct 1, 2024 Risk: medium
RedHill Biopharma Ltd. filed a Form 6-K on October 1, 2024, to report a press release regarding a deal with Medi-Cal. The filing does not contain specific finan
RedHill Biopharma Files 6-K on Coronavirus Update — Sep 30, 2024 Risk: medium
RedHill Biopharma Ltd. filed a Form 6-K on September 30, 2024, reporting on a press release titled "RedHill Announces New U.S. Coronavirus". The filing is for a
RedHill Biopharma Shareholders Approve All Resolutions — Sep 18, 2024 Risk: low
RedHill Biopharma Ltd. held its Annual General Meeting of Shareholders on September 18, 2024, where all proposed resolutions were approved. The company is a for
RedHill Biopharma Adjourns Annual Shareholder Meeting — Sep 17, 2024 Risk: low
RedHill Biopharma Ltd. announced the adjournment of its Annual General Meeting of Shareholders, originally scheduled for September 2024. The meeting has been po

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX